Literature DB >> 23846151

Hematopoietic cytokines as tumor markers in breast malignancies. A multivariate analysis with ROC curve in breast cancer patients.

S Ławicki, G E Będkowska, M Wojtukiewicz, M Szmitkowski.   

Abstract

PURPOSE: Plasma levels of selected hematopoietic cytokines: interleukin 3 ( IL-3), stem cell factor (SCF), granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF) and macrophage colony-stimulating factor (M-CSF), and the tumor marker carcinoma antigen 15-3 (CA 15-3) in breast cancer (BC) patients were investigated and compared to control groups: benign breast tumor patients and healthy subjects. MATERIAL/
METHODS: Cytokine levels were determined by ELISA, CA 15-3 - using the CMIA method.
RESULTS: A significant differences in the concentration of cytokines (with the exception of IL-3) and CA15-3 between the groups of BC patients, benign breast tumor patients and the healthy controls have been demonstrated. M-CSF has demonstrated higher or equal to CA 15-3 values of diagnostic sensitivity, specificity and the predictive values of positive and negative test results. The M-CSF area under the ROC curve (AUC) was the largest from all the cytokines tested and marginally lower than the AUC of CA 15-3.
CONCLUSION: These findings suggest the usefulness of M-CSF in diagnosing breast cancer, especially when discriminating between cancer and non-carcinoma lesions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23846151     DOI: 10.2478/ams-2013-0023

Source DB:  PubMed          Journal:  Adv Med Sci        ISSN: 1896-1126            Impact factor:   3.287


  7 in total

1.  Splenic and PB immune recovery in neoadjuvant treated gastrointestinal cancer patients.

Authors:  Kathryn E Cole; Quan P Ly; Michael A Hollingsworth; Jesse L Cox; Kurt W Fisher; James C Padussis; Jason M Foster; Luciano M Vargas; James E Talmadge
Journal:  Int Immunopharmacol       Date:  2022-02-21       Impact factor: 4.932

2.  Human splenic myeloid derived suppressor cells: Phenotypic and clustering analysis.

Authors:  Kathryn E Cole; Quan P Ly; Michael A Hollingsworth; Jesse L Cox; James C Padussis; Jason M Foster; Luciano M Vargas; James E Talmadge
Journal:  Cell Immunol       Date:  2021-03-01       Impact factor: 4.868

3.  M-CSF in a new biomarker panel with HE4 and CA 125 in the diagnostics of epithelial ovarian cancer patients.

Authors:  Grażyna Ewa Będkowska; Sławomir Ławicki; Ewa Gacuta; Przemysław Pawłowski; Maciej Szmitkowski
Journal:  J Ovarian Res       Date:  2015-05-03       Impact factor: 4.234

4.  Plasma levels and diagnostic utility of VEGF, MMP-9, and TIMP-1 in the diagnosis of patients with breast cancer.

Authors:  Sławomir Ławicki; Monika Zajkowska; Edyta Katarzyna Głażewska; Grażyna Ewa Będkowska; Maciej Szmitkowski
Journal:  Onco Targets Ther       Date:  2016-02-24       Impact factor: 4.147

5.  Diagnostic Value of Nonacid Nucleic Blood Tumor Marker Panels in Early Diagnosing Breast Cancer: A Systematic Review and Network Meta-Analysis.

Authors:  Vahid Raja; Ziba Farajzadegan; Marjan Mansourian; Khojaste Ghasemi; Mohammad Sadegh Aboutalebi; Rasool Nouri; Fariborz Mokarian
Journal:  Dis Markers       Date:  2022-02-03       Impact factor: 3.434

6.  ILs-3, 6 and 11 increase, but ILs-10 and 24 decrease stemness of human prostate cancer cells in vitro.

Authors:  Dandan Yu; Yali Zhong; Xiaoran Li; Yaqing Li; Xiaoli Li; Jing Cao; Huijie Fan; Yuan Yuan; Zhenyu Ji; Baoping Qiao; Jian-Guo Wen; Mingzhi Zhang; Gunnar Kvalheim; Jahn M Nesland; Zhenhe Suo
Journal:  Oncotarget       Date:  2015-12-15

Review 7.  The role of granulocyte colony‑stimulating factor in breast cancer development: A review.

Authors:  Li Liu; Yangyang Liu; Xiaohua Yan; Chong Zhou; Xiangyang Xiong
Journal:  Mol Med Rep       Date:  2020-03-10       Impact factor: 2.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.